BioBay Center To Help Medtech Firms Enter China
This article was originally published in PharmAsia News
With the aim of helping western companies tap into the fast-growing Chinese healthcare market, a new cross-border medical technology commercialization center planned in the Suzhou BioBay cluster will provide funding and assistance to selected U.S. and European companies for all aspects of product registration and commercialization in China.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.